表紙
市場調査レポート

原発性副甲状腺機能亢進症:世界の治験レビュー

Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 305092
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
原発性副甲状腺機能亢進症:世界の治験レビュー Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2014
出版日: 2014年05月30日 ページ情報: 英文 81 Pages
概要

当レポートでは、原発性副甲状腺機能亢進症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 原発性副甲状腺機能亢進症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位国
    • 欧州の上位5ヶ国
    • 北米の主要国
    • 中東・アフリカの上位国

G7諸国での治験件数:代謝性疾患の治験全体における原発性副甲状腺機能亢進症の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝性疾患の治験全体における原発性副甲状腺機能亢進症の割合

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 原発性副甲状腺機能亢進症治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Amgen Inc.
    • Kirin Holdings Company, Limited
  • 代表的な研究機関・病院の治験の概要
    • Columbia University
    • Medical University of Vienna
    • Postgraduate Institute of Medical Education and Research
    • Karolinska University Hospital
    • Rambam Health Care Campus
    • HaEmek Medical Center
    • The Medical University of Graz
    • 神戸大学
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • Nantes University Hospital

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2175CTIDB

GlobalData's clinical trial report, "Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2014" provides data on the Primary Hyperparathyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Primary Hyperparathyroidism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Primary Hyperparathyroidism. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Primary Hyperparathyroidism
    • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
    • Top Countries Contributing to Clinical Trials in Asia-Pacific
    • Top Five Countries Contributing to Clinical Trials in Europe
    • Top Countries Contributing to Clinical Trials in North America
    • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Clinical Trials by G7 Countries: Proportion of Primary Hyperparathyroidism to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Primary Hyperparathyroidism to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Primary Hyperparathyroidism Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Kirin Holdings Company, Limited
      • Clinical Trial Overview of Kirin Holdings Company, Limited
    • Clinical Trial Overview of Top Institutes / Government
      • Columbia University
      • Clinical Trial Overview of Columbia University
      • Medical University of Vienna
      • Clinical Trial Overview of Medical University of Vienna
      • Postgraduate Institute of Medical Education and Research
      • Clinical Trial Overview of Postgraduate Institute of Medical Education and Research
      • Karolinska University Hospital
      • Clinical Trial Overview of Karolinska University Hospital
      • Rambam Health Care Campus
      • Clinical Trial Overview of Rambam Health Care Campus
      • HaEmek Medical Center
      • Clinical Trial Overview of HaEmek Medical Center
      • The Medical University of Graz
      • Clinical Trial Overview of The Medical University of Graz
      • Kobe University
      • Clinical Trial Overview of Kobe University
      • The National Institute of Diabetes and Digestive and Kidney Diseases
      • Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases
      • Nantes University Hospital
      • Clinical Trial Overview of Nantes University Hospital
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region, 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Proportion of Primary Hyperparathyroidism to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Primary Hyperparathyroidism to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Primary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Kirin Holdings Company, Limited, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Karolinska University Hospital, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Rambam Health Care Campus, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by HaEmek Medical Center, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by The Medical University of Graz, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Kobe University, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Nantes University Hospital, 2014*

List of Figures

  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Proportion of Primary Hyperparathyroidism to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Primary Hyperparathyroidism to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Primary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top